Evidence map›Paper›PMID 40298994›Full record

ArticleAnnals of hematology2025

Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia.

Anna Turkina, Olga Vinogradova, Elza Lomaia, Evgeniya Shatokhina, Oleg Shukhov, Ekaterina Chelysheva, Dzhariyat Shikhbabaeva, Irina Nemchenko, Anna Petrova, Anastasiya Bykova and 10 more

Abstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Current Status of Molecularly Targeted Therapeutics in Blood Cancers.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Novel targeted therapies in chronic myeloid leukemia.Pharmaceutical science advances · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Anna TurkinaNational Medical Research Center for Haematology, Moscow, Russian Federation.
Olga VinogradovaBotkin Hospital, Moscow, Russian Federation.
Elza LomaiaAlmazov National Medical Research Centre, Saint-Petersburg, Russian Federation.
Evgeniya ShatokhinaMedical Research and Educational Center, Lomonosov Moscow State University, Moscow, Russia.
Oleg ShukhovNational Medical Research Center for Haematology, Moscow, Russian Federation.
Ekaterina ChelyshevaNational Medical Research Center for Haematology, Moscow, Russian Federation.
Dzhariyat ShikhbabaevaBotkin Hospital, Moscow, Russian Federation.
Irina NemchenkoNational Medical Research Center for Haematology, Moscow, Russian Federation.
Anna PetrovaNational Medical Research Center for Haematology, Moscow, Russian Federation.
Anastasiya BykovaNational Medical Research Center for Haematology, Moscow, Russian Federation.
Nadiya SiordiyaAlmazov National Medical Research Centre, Saint-Petersburg, Russian Federation.
Vasily ShuvaevA.Tsyb Medical Radiological Research Center, Obninsk, Russian Federation.
Ilya MikhailovCenter for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation, Moscow, Russia.
Fedor NovikovZelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Veronika ShulginaCity Clinical Hospital №31, Moscow, Russian Federation.
Andreas HochhausHematology/Oncology, University Hospital Jena, Jena, Germany.
Oliver OttmannSchool of Medicine, Cardiff University, Cardiff, UK.
Jorge CortesGeorgia Cancer Center, Augusta University, Augusta, GA, USA.
Robert Peter GaleCentre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.
Ghermes ChilovFusion Pharma, Nobelya st. 5, Moscow, 121205, Russian Federation. ghermes@fusion-pharma.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vamotinib (PF-114) is a 3rd -generation, ATP-competitive oral tyrosine kinase inhibitor (TKI) active against wild-type and mutated BCR::ABL1 isoforms including BCR::ABL1

Indexed as

Fusion Proteins, bcr-ablImidazolesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsAdultAgedAged, 80 and overBenzamidesFemaleHumansMaleMaximum Tolerated DoseMiddle AgedPyrimidinesYoung AdultBCR-ABL1 fusion protein, humanBenzamidesFusion Proteins, bcr-ablImidazolesN-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamideProtein Kinase InhibitorsPyrimidines

Identifiers

PMID40298994
PMCPMC12141164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.